Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 850 Shares of Stock

Key Points

• Jonathan Allan, General Counsel of Stoke Therapeutics, sold 850 shares of stock at an average price of $20.00, reducing his position by 3.43% and retaining 23,948 shares valued at approximately $478,960.
• Stoke Therapeutics reported earnings of ($0.40) per share for the last quarter, beating expectations, but revenue was lower than expected at $13.82 million compared to $31.51 million forecasted by analysts.
• The stock price of Stoke Therapeutics increased by 0.9% to $19.77, with analysts maintaining a general buy rating and a target price averaging around $25.57.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 850 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $20.00, for a total transaction of $17,000.00. Following the completion of the transaction, the general counsel directly owned 23,948 shares in the company, valued at $478,960. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jonathan Allan also recently made the following trade(s):

• On Wednesday, September 3rd, Jonathan Allan sold 6,345 shares of Stoke Therapeutics stock. The stock was sold at an average price of $20.07, for a total transaction of $127,344.15.
• On Tuesday, September 2nd, Jonathan Allan sold 14,922 shares of Stoke Therapeutics stock. The stock was sold at an average price of $20.14, for a total transaction of $300,529.08.
• On Wednesday, August 13th, Jonathan Allan sold 13,712 shares of Stoke Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $205,680.00.

Stoke Therapeutics Stock Performance

NASDAQ:STOK traded up $1.31 during mid-day trading on Monday, reaching $21.99. 1,434,514 shares of the company's stock were exchanged, compared to its average volume of 999,282. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $22.39. The firm has a market capitalization of $1.21 billion, a PE ratio of 25.87 and a beta of 1.14. The business's fifty day simple moving average is $15.13 and its two-hundred day simple moving average is $11.15.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. As a group, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on STOK. Chardan Capital reaffirmed a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the stock a "buy" rating in a research note on Monday, August 18th. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Wedbush increased their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Finally, HC Wainwright reduced their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Two equities research analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to MarketBeat.com, Stoke Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $25.57.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Toronto Dominion Bank bought a new stake in shares of Stoke Therapeutics in the 4th quarter valued at $35,001,000. Corient Private Wealth LLC bought a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at $7,489,000. RTW Investments LP increased its stake in shares of Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after acquiring an additional 471,240 shares in the last quarter. Checkpoint Capital L.P. increased its stake in shares of Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock valued at $4,859,000 after acquiring an additional 425,330 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new stake in shares of Stoke Therapeutics in the 1st quarter valued at $2,670,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.